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Radiation recall is defined as an inflammatory 
reaction on a region of the body previously irradi-
ated by radiotherapy [1–3] usually occurring after 
administration of certain trigger agents, such as 
antineoplastic and chemotherapy drugs, antituber-
culosis medication, antibiotics, tamoxifen, simvas-
tatin, and exposure to ultraviolet light [2]. The site 
most commonly affected by radiation recall is the 
skin, and in this case, it is described as radiation 
recall dermatitis (RRD) [3].
The manifestations of RDD vary in intensity and 
include maculopapular eruptions with erythema and 
vesicle formation, peeling of the affected skin and 
even severe skin necrosis, occurring days to years af-
ter the radiation, even when there was little or no re-
sidual reaction resulting from prior radiation sessions 
[1]. RRD is not necessarily an acute skin reaction 
during or at the end of the radiotherapy sessions [3].
AbstrAct
background: radiation recall dermatitis (rrD) is an inflammatory reaction in an area of the skin previously irradiated for can-
cer treatment. the reaction usually occurs following the administration of a cytotoxic drug. Manifestations range from mild 
to severe, resulting in tissue necrosis. It is treated with removal of the probable causative agent, daily dressings and surgical 
debridement of the necrotic area.
case presentation: a 54-year-old woman had a previous diagnosis of intraductal carcinoma in situ, and had been submitted 
to lumpectomy and adjuvant radiotherapy and hormonal therapy. one year after surgery, sores suggestive of herpes zoster 
infection developed, and treatment with acyclovir was started. at the same time, there was the onset of pain and fever. In 
the skin area previously irradiated, there was breast hardening, skin infiltration and serosanguinolent discharge. an incisional 
biopsy was performed to rule out radioinduced sarcoma. the patient was treated with surgical debridement.
conclusions: this case report describes acyclovir as a possible trigger of rrD, a rare condition that could have been mistaken 
for an eruption with other causes. In this case, the dermatitis reaction was confined to the previously irradiated area of the skin, 
which suggested radiation recall. a better understanding of the condition’s mechanism and about the possible joint effects of 
drugs and radiotherapy on the skin is necessary.
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Radiotherapy uses high-energy or gamma rays 
directly on the tumor or on the affected site after 
the surgical intervention, promoting local control 
of the tumor and the death of cancer cells that re-
mained after surgery [4, 5]. Radiotherapy typically 
causes sensitivity up to 7 days after the sessions. 
RRD, instead, is triggered after the use of drugs [6].
RRD is a well-known but poorly understood 
phenomenon, mainly because of the lack of animal 
models. There is a myriad of hypotheses that explain 
the pathophysiological of RDD, like vascular dam-
age, epithelial stem cell inadequacy, epithelial stem 
cell sensitivity and drug hypersensitivity reaction 
[7]. The theory of alteration in vascular permeabil-
ity argues that previous radiotherapy changes the 
pharmacokinetics of the inducing drug, promoting 
the inflammatory reaction [6]. The epithelial stem 
cell inadequacy hypothesis proposes that the ra-
diation reduces the number of stem cell and overall 
skin stability, yielding a cell proliferation response 
triggered by the drug [8, 9]. The epithelial stem cell 
sensitivity hypothesis relies on the fact that radia-
tion promotes a stable long-term alteration in the 
epithelial cell phenotype [10], which in some cases 
promotes a faster rate cell cycling, increasing the 
number of dead cells [11]. The most acceptable 
hypothesis, however, is drug hypersensitivity, where 
the recall is caused by an idiosyncratic drug reac-
tion activating inflammatory pathways that are not 
immune-dependent [7, 12].
In this report, we describe a case of RRD in a pa-
tient treated for breast cancer. The woman was op-
erated for intraductal carcinoma one year before 
the onset of RRD and received prophylactic treat-
ment with radiotherapy and tamoxifen. The RRD 
event reported here was triggered by oral acyclovir, 
an antiviral drug with viral replication inhibiting 
the activity of herpes simplex virus type 1 (HSV-1), 
2 (HSV-2) and varicella-zoster virus (VZV) [3]. The 
drug has, as common adverse events, malaise, nau-
sea, diarrhea, headache and, in rarer cases, immune 
thrombocytopenia [3]. However, the relationship 
with RRD has not yet been described.
case presentation
A 54-year-old white woman sought medical at-
tention in September 2015 in a city in the interior 
of the state of São Paulo with a complaint of sponta-
neous nipple bleeding associated with pain during 
physical exercise. She worked as a seamstress. The 
patient was married, had had four pregnancies, all 
cesareans, and no family history of breast cancer, 
but had a history of ovarian cyst surgical removal. 
She reported menopause at 42 years.
On physical examination, the breasts were sym-
metrical, with no nodules visualizations, architec-
tural distortions or suspicion of calcifications. There 
was uniductal bloody papillary effusion on the left 
side, with the trigger point at 6 o’clock. Mammog-
raphy and breast ultrasonography were performed, 
both coming with a BI-RADS 1 report. Despite 
imaging exams showing normality, the persistence 
of the suspicious serosanguinous secretion led the 
patient to be referred to the Regional Hospital’s 
mastology outpatient clinic at Presidente Prudente, 
São Paulo state, with the indication of lumpecto-
my/resection of the main ducts in the left breast.
The surgical procedure resected a fragment of 
the breast’s tissue for histopathological evaluation. 
The final diagnosis was intraductal carcinoma in 
situ of low grade, with a 3-mm single focus, of 
cribriform standard, with ductal ectasia, chronic 
mastopathy alterations, columnar cell alterations 
with foci of dystrophic calcification, and typical 
ductal hyperplasia with a 1-mm single focus and 
free circumferential surgical margins. The immu-
nohistochemistry evaluation of the same material 
assessed the expression of C-erbB-2 (Her-2 SP3), 
Ki-67 (Mab SP6), estrogen receptor (SP1) and pro-
gesterone Receptor (SP2). The immunohistochem-
istry profile result showed positivity for estrogen 
receptors in about 80% of neoplastic cells, proges-
terone receptors in about 30%, high rate of cell 
proliferation measured by Ki-67 (over 14%) and 
negativity for overexpression of epidermal growth 
Her-2 factor. 
After hospital discharge, the patient was referred 
to radiotherapy, performed in 33 sessions, in the 
total dose of 5040 cGy (180 cGy/day). The patient 
also started the use of tamoxifen 20 mg/day as hor-
monal therapy.
One year after the surgery, the patient visited 
a dermatologist complaining of sores on the left 
breast, local hardening and unchecked fever for 
about 15 days. She reported being diagnosed as 
having herpes zoster by a pharmacist in a drug-
store near home and that she had started to use 
acyclovir (200 mg, every 6 hours during 14 days). 
During acyclovir use, breast pain started, and the 
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general clinical condition worsened. Because the 
patient self-medicated, there was no possibility to 
perform a microbiological analysis of pathological 
tissue to confirm herpes virus presence. The der-
matologist noticed, on physical examination, ery-
thema, skin hardening and infiltration throughout 
the left breast, and the presence of serosanguinolent 
discharge, without signs of herpes zoster or other 
skin problems. She was then referred back to the 
mastologist (Fig. 1A).
At the Regional Hospital, an investigation was 
conducted with chest and upper abdomen comput-
ed tomography, and biopsy of the dermal material 
from the left breast for anatomopathological exami-
nation. At the macroscopy exam, the first skin frag-
ment taken for pathological examination was the 
size of 1.0 cm × 0.6 cm, with a finely grainy surface, 
brownish color and firm and elastic consistency; in 
the cuts, the surface was grayish-white. The second 
fragment was sized 0.6 cm × 0.4 cm, presented on 
the surface a 0.3 cm raised lesion, of vegetative as-
pect, gray-brown and firm and elastic consistency; 
in the cuts; the surface was grayish-brown.
The histopathological evaluation indicated acute 
erosive dermatitis, with vascular alterations sugges-
tive of radiotherapy effects and absence of neoplasia 
(Fig. 2A and 2B). Imaging exams did not show 
signs of local or distant tumor recurrence. After 
complete anamnesis and complementary exams, 
the diagnostic hypothesis was radiation recall.
The patient was treated with repeated surgical 
debridements (Fig. 1B) associated with papain and 
SAF-gels (Fig. 1C) as recommended by the plas-
tic surgery team. The patient was also referred for 
treatment with a hyperbaric chamber (Fig. 1D), 
and underwent 20 sessions. Breast reconstruction 
surgery with a graft has been scheduled.
Discussion and conclusion
The patient in the RRD case reported here had 
a previous diagnosis of grade 2 carcinoma in situ 
with free margins and positive estrogen hormone 
receptor (ER-positive), treated with oncological 
surgery associated with radiotherapy and use of 
tamoxifen. According to Fischer et al., protocol 
B-17 [13], the addition of radiotherapy as an adju-
vant treatment after surgery results in the reduction 
of local recurrence and, significantly, invasive car-
cinoma, playing a role as a preventive agent, since 
a B
c D
Figure 1. clinical evolution of the patient with radiation 
recall dermatitis. A. Hyperemic breast with serosanguinolent 
secretion seen one year after breast cancer treatment.  
b. aspect of the breast after surgical debridement. 
c. supportive treatment with papain and saF-gel. 
D. aspect of breast healing process between hyperbaric 
therapy sessions.
Figure 2. Histopathological evaluation of the patient with 
radiation recall dermatitis. A. Hematoxylin-eosin stain with 
40 × magnification showing intense neutrophilic exudate 
throughout the epidermis and dermis. b. Hematoxylin-eosin
stain with 100 × magnification showing ulcerated epidermis 
with foci of parakeratosis and acanthosis, liquefactive and 
atypical reactions of the basal layer. In the dermis, fibrosis 
and elastosis are noted, with intense fibrinoid exudate and 
vascular thickening with extravasation of red blood cells
a
B
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it destroys cancer cells and affects the precursors of 
these cells [13–15]. After 12 years of follow-up of 
patients submitted to the protocol B-17, the reduc-
tion in the annual incidence rate of all ipsilateral 
tumors, invasive or not, remained at 58% per year. 
The results found in the treatment of ductal car-
cinoma in situ by the European Organization for 
Research and Treatment of Cancer (EORTC), are 
similar to NSABP B17, in which a reduction in lo-
cal recurrence rate was observed when the group 
submitted to the lumpectomy was treated with ra-
diotherapy [15]. The use of tamoxifen, a selective 
estrogen receptor modulator [16], in patients with 
positive estrogen receptors provides a lower rate of 
ipsilateral recurrence, as well as a reduction in the 
occurrence of a new contralateral tumor and recur-
rence in the form of invasive carcinoma, according 
to the NSABP protocol B24 [13, 15, 17]. Therefore, 
both treatments were well justified for this patient 
at the time.
Only one report describes recall dermatitis re-
lated to the use of acyclovir, with some uncom-
mon adverse skin reactions described with the use 
of acyclovir: vesicular dermatitis involving palms 
and soles, peripheral edema, erythema nodosum, 
rashes, hyperhidrosis, acne, lichenoid and skin 
rash, pruritus, urticaria, vasculitis and alopecia1. 
In that case, published in 2002, the rash appeared 
on the seventh day after oral acyclovir use, with 
small macules and erythematous papules involving 
the trunk and limbs symmetrically and bilaterally, 
along with the dermatomes previously affected by 
herpes varicella zoster [1]. However, the charac-
teristics of active herpes varicella-zoster infection 
were not histopathologically verified by the authors, 
although the cutaneous eruption secondary to acy-
clovir was more intense in regions previously af-
fected by the virus. Furthermore, the area of lesions 
had not been irradiated previously [1].
RRD is widely described in the literature, oc-
curring in patients who underwent radiotherapy 
with symptoms precipitated after the use of specific 
drugs, such as actinomycin D, adriamycin, bleomy-
cin, docetaxel, etoposide, 5-fluorouracil, gemcitabi-
ne, hydroxyurea, methotrexate, paclitaxel, simvas-
tatin, tamoxifen, and antituberculosis medication, 
such as rifampicin, isoniazid and pyrazinamide, 
trimetrexate and vinblastine, and also other trigger-
ing agents, such as ultraviolet radiation [6, 7]. The 
radiodermatitis presents in four degrees of toxicity: 
grade 1 (mild) with erythema, pruritus and dry 
flaking, grade 2 (mild-moderate) with pain, ede-
ma, urticaria or the appearance of vesicles, grade 
3 (moderate) with wet desquamation and grade 4 
(severe) with necrosis, ulcer or hemorrhage [7, 18]. 
The pathophysiology of RRD is unknown, but 
several hypotheses are described. One of the hy-
potheses is that changes in vascular permeability 
in the irradiated area would alter the drug’s kinet-
ics in that region, creating a hypersensitivity reac-
tion, leading to acute inflammation [19]. Another 
accepted theory is related to radiation changes in 
localized cellular DNA, promoting the increased 
expression of inflammatory cytokines, such as in-
terleukins 1 and 6 (IL-1, IL-6) and tumor necrosis 
factor-alpha (TNF-alpha), in the presence of the 
event-inducing drug [20].
The patient here described, after acyclovir use 
for the treatment of unproven herpes zoster infec-
tion, presented something different from a drug 
eruption: the onset of breast pain, dermal lesions 
and fever (not measured), progressing to grade 4 
radiodermatitis, with serosanguinolent secretion 
accompanied by erythema, hardening and infiltra-
tion in the skin of the left breast, in areas previously 
irradiated. There was no sign of herpes zoster and 
no involvement of the breast tissue. Once the prob-
able causative agent (acyclovir) was removed, and 
daily dressings and surgical debridement were per-
formed, the patient’s condition improved without 
complications. Imaging exams excluded the pos-
sibility of locoregional or distant tumor recurrence. 
The anatomopathological examination indicated 
acute erosive dermatitis with vascular alterations 
suggestive of radiotherapy effect and absence of 
neoplasia in the material, which suggested RRD 
due to the use of acyclovir as a diagnosis. 
For the treatment of ductal carcinoma in situ, 
whenever possible, the conservative treatment is 
the choice, followed by radiation therapy and en-
docrine therapy to reduce the risk of local, con-
tralateral recurrence and invasive carcinoma [13]. 
However, in some cases, total mastectomy is indi-
cated, and immediate breast reconstruction should 
be considered [13]. To achieve a therapeutic suc-
cess and prevent recurrence, clinical and imaging 
evaluation should be performed periodically, with 
patient informed about the risks.
The manifestation of RRD is described in dif-
ferent degrees of tissue involvement induced by 
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different drug classes. However, it has not been 
described before in association with the use of acy-
clovir specifically. There are no precise descriptions 
of the pharmacological agents or classes of drugs 
that can induce RRD. Hence, for optimal diagnosis 
and management of patients with RRD, it is neces-
sary to consider all the possible adverse effects of 
medications used after radiation, even months after 
radiotherapy. Also, it is advisable to use the low-
est effective radiotherapy dose for the disease. This 
case report describes acyclovir as a possible trig-
ger of radiation recall dermatitis, a rare condition 
that could have been mistaken for an eruption with 
other causes. In the present case, the dermatitis 
reaction was confined to the previously irradiated 
area of the skin, which suggested radiation recall 
dermatitis. 
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